Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Phase 1 Unknown 24 enrolled Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Beijing GoBroad Hospital Management Co.,Ltd · collab Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.

Timeline

Start: 2021-04-15
Primary completion: 2023-04-07
Completion: 2024-04-07

Publications

Background Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR7-T Cells	Cell therapy	1 cells/kg	—
Subject	CAR7-T Cells	Cell therapy	2 cells/kg	—
Background	Cyclophosphamide	Other / unclassified	250 mg/kg	—
Background	Fludarabine	Small molecule	30 mg/kg	—

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Summary

Timeline

Publications

Drugs

Indications